Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Real world management of multiple myeloma patients

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
Real world management of multiple myeloma patients ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )
8 Dec 2020

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results

Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results ( Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany )
7 Dec 2020

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients

Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain
Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients ( Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain )
7 Dec 2020

FORTE trial: Impact of minimal residual disease on multiple myeloma patients

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy
FORTE trial: Impact of minimal residual disease on multiple myeloma patients ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )
7 Dec 2020

Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
7 Dec 2020

Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma

Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA
Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma ( Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA )
7 Dec 2020

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020

Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol

Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol ( Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands )
7 Dec 2020

Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study

Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy
Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study ( Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy )
6 Dec 2020

Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL

Prof David Teachey - The University of Pennsylvania, Rutledge, USA
Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL ( Prof David Teachey - The University of Pennsylvania, Rutledge, USA )
6 Dec 2020

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia

Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia ( Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA )
5 Dec 2020